Mild cognitive impairment and early Alzheimer's disease eligibility for disease modification therapies in a tertiary centre for cognitive disorders: A simultaneous real‐word study on aducanumab and lecanemab - Logroscino, G.; Urso, D.; Gnoni, V.; Giugno, A.; Vilella, D.; Castri, A.; Barone, R.; Nigro, S.; Zecca, C.; De Blasi, R.; Introna, A. (European journal of neurology, 2025)
Keywords: aducanumab; Aged; Aged, 80 and over; Alzheimer; Alzheimer Disease - drug therapy; Alzheimer's disease; Amyloid; Antibodies, Monoclonal, Humanized - therapeutic use; Biomarkers; Clinical trials; Cognitive ability; Cognitive Dysfunction - drug therapy; Criteria; Cross-Sectional Studies; Dementia disorders; disease‐modifying; Disorders; DMT; FDA approval; Female; Humans; Impairment; Italy; lecanemab; Male; Middle Aged; Monoclonal antibodies; Neurodegenerative diseases; Tertiary Care Centers; Italy; lecanemab; DMT; aducanumab; disease‐modifying; Alzheimer